Clinical Trials

Multiple Myeloma Cancer Trials

Learn More About Our Multiple Myeloma Cancer Trials

  • 1 54767414SMM3001 Show More

    54767414SMM3001 – A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma.

    1. WHAT TYPE OF CANCER? WHAT STAGE?
    Smoldering Multiple Myeloma.

    2. WHO IS ELIGIBLE?
    Diagnosed within 5 years.

    3. HOW WILL I BE TREATED?
    Daratumumab (an anti-body-based drug, directed against CD38).

    For Physicians: More information about this specific trial at clinicaltrials.gov

EJGH Trials Send an Inquiry

Click here